Surfactant Protein (e.g., Sp-a, Sp-b, Etc.) Or Derivative Affecting Or Utilizing Patents (Class 514/15.5)
  • Patent number: 9815869
    Abstract: The present invention relates to synthetic lung surfactant compositions that include a novel surface active peptide and a phospholipid, including phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, naturally occurring phospholipids, or a combination thereof. Uses of the surfactant compositions of the present invention to treat endogenous surfactant dysfunctional or deficient lung tissue and to deliver therapeutic agents are also disclosed.
    Type: Grant
    Filed: February 11, 2013
    Date of Patent: November 14, 2017
    Assignees: University of Rochester, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Inventors: Robert H. Notter, Alan J. Waring, Frans J. Walther, Larry M. Gordon, Zhengdong Wang
  • Patent number: 9814720
    Abstract: A method of inhibiting IL-17 expression in neutrophils of a subject in need thereof includes administering to neutrophils of the subject a therapeutically effective amount of agent that inhibits STAT3 mediated IL-17 expression in the neutrophils of the subject.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: November 14, 2017
    Assignee: Case Western Reserve University
    Inventor: Eric Pearlman
  • Patent number: 9492503
    Abstract: Surfactant protein D (SP-D) is a member of the collectin family of collagenous lectin domain-containing proteins that is expressed in epithelial cells of the lung. Described herein are methods and compositions for the treatment of disorders associated with lung injury, including methods and compositions for the treatment of bronchopulmonary disorder (BPD).
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: November 15, 2016
    Assignee: Children's Hospital Medical Center
    Inventors: Jeffrey A. Whitsett, Machiko Ikegami
  • Patent number: 9289388
    Abstract: The disclosure provides a drug composition formulated for inhalation comprising a conjugate of a surface active agent and a pulmonary active drug. The surface active agent has an affinity for the human alveolar/gas interface and comprises at least a portion of a mammalian lung surfactant of a mimic thereof. The disclosure also provides a method of treating a subject suffering from or at risk of suffering from a lung disease comprising administering to the subject a conjugate comprising a drug for lung treatment and a surface active agent by inhalation in an amount effective to induce a drug effect in the lungs.
    Type: Grant
    Filed: December 10, 2009
    Date of Patent: March 22, 2016
    Assignee: Paka Pulmonary Pharmaceuticals, Inc.
    Inventor: Frank Guarnieri
  • Publication number: 20150139944
    Abstract: Provided is a separatome-based recombinant peptide, polypeptide, and protein expression and purification platform based on the juxtaposition of the binding properties of host cell genomic peptides, polypeptides, and proteins with the characteristics and location of the corresponding genes on the host cell chromosome, such as that of E. coli, yeast, Bacillus subtilis or other prokaryotes, insect cells, mammalian cells, etc. This platform quantitatively describes and identifies priority deletions, modifications, or inhibitions of certain gene products to increase chromatographic separation efficiency, defined as an increase in column capacity, column selectivity, or both, with emphasis on the former. Moreover, the platform provides a computerized knowledge tool that, given separatome data and a target recombinant peptide, polypeptide, or protein, intuitively suggests strategies leading to efficient product purification.
    Type: Application
    Filed: October 23, 2014
    Publication date: May 21, 2015
    Inventors: Ellen M. Brune, Robert R. Beitle, Mohammad M. Ataai, Patrick R. Bartlow, Ralph L. Henry
  • Publication number: 20150125515
    Abstract: The present invention relates to synthetic lung surfactant compositions that include a novel surface active peptide and a phospholipid, including phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, naturally occurring phospholipids, or a combination thereof. Uses of the surfactant compositions of the present invention to treat endogenous surfactant dysfunctional or deficient lung tissue and to deliver therapeutic agents are also disclosed.
    Type: Application
    Filed: February 11, 2013
    Publication date: May 7, 2015
    Applicant: UNIVERSITY OF ROCHESTER
    Inventors: Robert H. Notter, Alan J. Waring, Frans J. Walther, Larry M. Gordon, Zhengdong Wang
  • Patent number: 8933032
    Abstract: Surfactant protein D (SP-D) is a 43-kDa member of the collectin family of collagenous lectin domain-containing proteins that is expressed in epithelial cells of the lung. Described herein are methods and compositions for the treatment of disorders associated with lung injury, including methods and compositions for the treatment of bronchopulmonary disorder (BPD) using recombinant human surfactant protein D and surfactant formulations.
    Type: Grant
    Filed: February 4, 2011
    Date of Patent: January 13, 2015
    Assignee: Children's Hospital Medical Center
    Inventors: Jeffrey A. Whitsett, Machiko Ikegami
  • Publication number: 20140378383
    Abstract: The disclosure provides a drug composition formulated for inhalation comprising a conjugate of a surface active agent and a pulmonary active drug. The surface active agent has an affinity for the human alveolar/gas interface and comprises at least a portion of a mammalian lung surfactant of a mimic thereof. The disclosure also provides a method of treating a subject suffering from or at risk of suffering from a lung disease comprising administering to the subject a conjugate comprising a drug for lung treatment and a surface active agent by inhalation in an amount effective to induce a drug effect in the lungs.
    Type: Application
    Filed: March 10, 2014
    Publication date: December 25, 2014
    Inventor: Frank Guarnieri
  • Patent number: 8883730
    Abstract: The present invention provides the use of formulation with surfactant protein-D (SP-D) in the modulation of activity of human eosinophils derived from hypereosinophilic patients to an increased activation state and increased apoptosis. Accordingly the utility of the invention can be extended in human subjects in resolution of eosinophilic inflammations in related diseases and disorders like neuromuscular and respiratory diseases with eosinophilia other than airway-hyperresponsiveness, allergy and asthma, hypereosinophilic leukemias, hypereosinophilc syndromes (rare hematological diseases), skin diseases like eosinophilia-Myalgia syndrome, eosinophilic fascitis, capillary leak syndromes (IL-2), Churg-Strauss syndrome, toxic oil syndrome, parasitosis, etc., where a large number of stimulated eosinophils accumulate and release a series of growth factors, cytokines, chemokines, bioactive lipid mediators, toxic oxygen metabolites.
    Type: Grant
    Filed: September 28, 2007
    Date of Patent: November 11, 2014
    Assignee: Council of Scientific and Industrial Research
    Inventors: Lakshna Mahajan, Taruna Madan, Puranam Usha Sarma, Uday Kishore
  • Patent number: 8865643
    Abstract: We describe an rspd(n/CRD) polypeptide, fragment, homologue, variant or derivative thereof for use in a method of treatment or prophylaxis of a disease. A method of treating an individual suffering from a disease or preventing the occurrence of a disease in an individual is also described, in which the method comprises administering to the individual a therapeutically or prophylactically effective amount of an rspd (n/CRD) polypeptide, fragment, homologue, variant or derivative thereof. Preferably, the rspd (n/CRD) polypeptide and nucleic acid comprise SEQ ID NO: 1 and SEQ ID NO: 2, respectively.
    Type: Grant
    Filed: February 3, 2011
    Date of Patent: October 21, 2014
    Assignee: Medical Research Council
    Inventors: Howard Clark, Palaniyar Nadesalingam, Kenneth B. Reld, Peter Strong
  • Publication number: 20140256613
    Abstract: Peptide compositions are disclosed that include fragments of surfactant protein-A, or a derivative thereof, wherein the fragment binds to TLR4. Methods of producing and using the peptide compositions are also disclosed.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 11, 2014
    Applicant: The Board of Regents of the University of Oklahoma
    Inventor: Shanjana Awasthi
  • Publication number: 20140243272
    Abstract: An isolated protein selected from the group consisting of (i) proteins comprising an amino acid sequence having at least 70% identity to the C-terminal domain of lung surfactant protein C precursor (CTproSP-C, “CTC”) from a mammal; and (ii) proteins comprising an amino acid sequence having at least 70% identity to the Brichos domain of CTproSP-C from a mammal, is disclosed for treatment of Alzheimer's disease in a mammal, including man.
    Type: Application
    Filed: May 16, 2014
    Publication date: August 28, 2014
    Applicant: ALPHABETA AB
    Inventor: Jan Johansson
  • Publication number: 20140142021
    Abstract: The present invention is directed to a reconstituted surfactant comprising a phospholipid mixture, and a combination of particular analogues of the native surfactant protein SP-C with analogues of the native surfactant protein SP-B. The invention is also directed to pharmaceutical compositions and kits thereof and to its use for the treatment or prophylaxis of RDS and other respiratory disorders.
    Type: Application
    Filed: November 20, 2013
    Publication date: May 22, 2014
    Applicant: CHIESI FARMACEUTICI S.p.A
    Inventors: JAN JOHANSSON, TORE CURSTEDT
  • Publication number: 20140135268
    Abstract: Surfactant protein D (SP-D) is a member of the collectin family of collagenous lectin domain-containing proteins that is expressed in epithelial cells of the lung. Described herein are methods and compositions for the treatment of disorders associated with lung injury, including methods and compositions for the treatment of bronchopulmonary disorder (BPD).
    Type: Application
    Filed: October 24, 2013
    Publication date: May 15, 2014
    Applicant: Children's Hospital Medical Center
    Inventors: Jeffrey A. Whitsett, Machiko Ikegami
  • Patent number: 8673842
    Abstract: The present invention provides spreading agents based on sequence-specific oligomers comprising a peptoid, a peptide-peptoid chimera, a retropeptoid or a retro(peptoid-peptide) chimera, and methods for using the same, including for the treatment of respiratory distress of the lungs. The spreading agents are sequence-specific oligomers, including retrosequence-specific oligomers, based on a peptide backbone, that are designed as analogs of surfactant protein-B or surfactant protein-C.
    Type: Grant
    Filed: February 13, 2012
    Date of Patent: March 18, 2014
    Assignees: Chiron Corporation
    Inventors: Annelise E. Barron, Ronald N. Zuckermann, Cindy W. Wu
  • Patent number: 8642034
    Abstract: The disclosure relates to methods of treating an infant at risk of developing bronchopulmonary dysplasia, including premature infants, by administering a TGF-? antagonist during the perinatal period, including the prenatal period and/or the postnatal period. For administration during the prenatal period, the TGF-? antagonist can be administered either directly to the infant in utero, or indirectly by administration to the mother.
    Type: Grant
    Filed: October 3, 2007
    Date of Patent: February 4, 2014
    Assignee: Genzyme Corporation
    Inventors: James B. Streisand, Jesse D. Roberts, Jr.
  • Patent number: 8529939
    Abstract: The present invention relates to mucoadhesive drug delivery devices and their methods of preparation and use. More specifically the present invention relates to mucoadhesive drug delivery devices comprising one or more biocompatible purified proteins combined with one or more biocompatible solvents and one or more mucoadhesive agents. The mucoadhesive drug delivery devices may also include one or more pharmacologically active agents. The drug delivery devices of the present invention adhere to mucosal tissue, thereby providing a vehicle for delivery of the pharmacologically active agent(s) through such tissue.
    Type: Grant
    Filed: December 8, 2004
    Date of Patent: September 10, 2013
    Assignee: Gel-Del Technologies, Inc.
    Inventors: David B. Masters, Eric P. Berg
  • Publication number: 20130184198
    Abstract: Synthetic pulmonary surfactant compositions comprising dipalmitoyl phosphatidylcholine, phosphatidylglycerol, and essentially neutral lipid, and having essentially no 1-palmitoyl 2-oleoyl phosphatidylglycerol and essentially no palmitic acid are provided. Methods for treating respiratory disease are also provided comprising administering a therapeutically effective amount of a synthetic pulmonary surfactant comprising dipalmitoyl phosphatidylcholine, phosphatidylglycerol, and essentially neutral lipid, and having essentially no 1-palmitoyl 2-oleoyl phosphatidylglycerol and essentially no palmitic acid.
    Type: Application
    Filed: November 29, 2012
    Publication date: July 18, 2013
    Applicant: DISCOVERY LABORATORIES, INC.
    Inventor: Discovery Laboratories, Inc.
  • Publication number: 20130109627
    Abstract: SP-C peptoid compounds, lung surfactant compositions and related surfactant replacement therapies. Such SP-C peptoids can mimic lung surfactant protein C, and can be used in conjunction with biomimetic SP-B compounds over a range of lung surfactant compositions.
    Type: Application
    Filed: April 1, 2011
    Publication date: May 2, 2013
    Applicant: Northwestern University
    Inventors: Annelise E. Barron, Nathan J. Brown
  • Publication number: 20130079275
    Abstract: Reconstituted surfactants comprising a lipid carrier, a polypeptide analog of the native surfactant protein SP-C, and a polypeptide analog of the native surfactant protein SP-B are useful for the treatment and/or prophylaxis of RDS and other respiratory disorders.
    Type: Application
    Filed: April 10, 2012
    Publication date: March 28, 2013
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: JAN JOHANSSON, TORE CURSTEDT, LENA STALAND JONSSON, JOAKIM ROBERTSON, SOEREN ROBERTSON, MAGNUS ROBERTSON, CHARLOTTE ROBERTSON, GERTIE ROBERTSON GROSSMANN
  • Publication number: 20130065833
    Abstract: SP-B peptoid compounds, lung surfactant compositions and related surfactant replacement therapies. Such SP-B peptoids can mimic lung surfactant protein B, and can be used in conjunction with biomimetic SP-C compounds over a range of lung surfactant compositions.
    Type: Application
    Filed: March 21, 2011
    Publication date: March 14, 2013
    Applicant: Northwestern University
    Inventors: Annelise E. Barron, Michelle Dohm, Shannon L. Servoss
  • Patent number: 8357657
    Abstract: Administration of a modified natural surfactant in combination with a corticosteroid is effective for the prevention of bronchopulmonary dysplasia (BPD) and lowers the markers of pulmonary oxidative stress.
    Type: Grant
    Filed: May 25, 2010
    Date of Patent: January 22, 2013
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Massimo Giossi, Roberta Razzetti, Paolo Chiesi
  • Publication number: 20120258918
    Abstract: The present invention provides spreading agents based on sequence-specific oligomers comprising a peptoid, a peptide-peptoid chimera, a retropeptoid or a retro(peptoid-peptide) chimera, and methods for using the same, including for the treatment of respiratory distress of the lungs. The spreading agents are sequence-specific oligomers, including retrosequence-specific oligomers, based on a peptide backbone, that are designed as analogs of surfactant protein-B or surfactant protein-C.
    Type: Application
    Filed: February 13, 2012
    Publication date: October 11, 2012
    Inventors: Annelise E. Barron, Ronald N. Zuckermann, Cindy W. Wu
  • Publication number: 20120220531
    Abstract: Surfactant protein D (SP-D) is a member of the collectin family of collagenous lectin domain-containing proteins that is expressed in epithelial cells of the lung. Described herein are methods and compositions for the treatment of disorders associated with lung injury, including methods and compositions for the treatment of bronchopulmonary disorder (BPD).
    Type: Application
    Filed: February 3, 2012
    Publication date: August 30, 2012
    Applicant: CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Jeffrey A. Whitsett, Machiko Ikegami
  • Patent number: 8221772
    Abstract: Methods and compositions to enhance mucus clearance and to treat pulmonary lung disorders such as cystic fibrosis are disclosed. The methods utilize compositions including synthetic pulmonary surfactants having one or more phospholipids and a synthetic polypeptide, administered alone or combined with hyperosmotic agents, to patients in an amount effective to enhance mucus clearance.
    Type: Grant
    Filed: September 19, 2007
    Date of Patent: July 17, 2012
    Assignee: Discovery Laboratories Inc.
    Inventors: Mark. E. Johnson, Robert Segal, Thomas Hofmann, Robert J. Capetola
  • Patent number: 8217004
    Abstract: According to the present invention, there is provided a method of sequestering micronutrients when used to provide the micronutrients to a plant, which comprises applying to an area of the plant or soil/substrate surrounding the plant an effective amount of a plant fertilizer composition comprising a surfactant, such as general formula (III), that is capable of forming coordinate bonds with micronutrients.
    Type: Grant
    Filed: March 15, 2006
    Date of Patent: July 10, 2012
    Assignee: Adelaide Research and Innovation Pty. Ltd.
    Inventors: Mike McLaughlin, Samuel Stacey, Enzo Lombi
  • Publication number: 20120142596
    Abstract: The present invention provides a composition for stimulating the mobilization of endothelial precursor cells, which comprises substance-P (SP). Substance-P according to the invention exhibits an activity of stimulating the mobilization of endothelial precursor cells from the bone marrow, thereby stimulating vasculogenesis. Thus, substance-P exhibits excellent effects on the prevention or treatment of diseases, including myocardial infarction, angina, ischemic stroke, cerebrovascular dementia, cerebral infarction, sequelae of cerebral injury, spinal cord injury, sequelae of spinal nerve injury, degenerative diseases, sequelae of cerebral infarction, peripheral nerve disorders, presbyopia, degenerative hearing loss, sequelae of brain surgery, and diabetic ulcer, which are accompanied by ischemic vascular injury or traumatic vascular injury.
    Type: Application
    Filed: August 12, 2010
    Publication date: June 7, 2012
    Inventors: Young Sook Son, Hyun Sook Hong
  • Patent number: 8173599
    Abstract: The present invention relates to a spray-dried composition comprising as an active ingredient at least one member protein of the collectin family or its functional equivalent for treating and preventing microbial infectious diseases. The present invention also relates to a method for producing the same composition. The composition produced by the method of the present invention is effective in suppressing infections caused by viruses, bacteria, fungi, and parasites. Since the composition is developed in a form suitable for inhalation, it can directly provide the active ingredient to the sites of infection from these microbes, and thus treat and prevent respiratory infections and external wounds.
    Type: Grant
    Filed: May 18, 2006
    Date of Patent: May 8, 2012
    Assignee: Dobeel Corporation
    Inventors: Hong Mo Moon, Jung Sun Yum, Byung Cheol Ahn, Joo Youn Lee
  • Patent number: 8148492
    Abstract: The present invention is directed to a reconstituted surfactant comprising a lipid carrier, a polypeptide analog of the native surfactant protein SP-C, and a polypeptide analog of the native surfactant protein SP-B. The invention is also directed to the pharmaceutical compositions thereof and to a use thereof in the treatment or prophylaxis of RDS and other respiratory disorders.
    Type: Grant
    Filed: August 11, 2008
    Date of Patent: April 3, 2012
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Jan Johansson, Tore Curstedt, Bengt Robertson, Maurlzio Delcanale
  • Patent number: 8114830
    Abstract: The present invention provides spreading agents based on sequence-specific oligomers comprising a peptoid, a peptide-peptoid chimera, a retropeptoid or a retro(peptoid-peptide) chimera, and methods for using the same, including for the treatment of respiratory distress of the lungs. The spreading agents are sequence-specific oligomers, including retrosequence-specific oligomers, based on a peptide backbone, that are designed as analogs of surfactant protein-B or surfactant protein-C.
    Type: Grant
    Filed: May 2, 2005
    Date of Patent: February 14, 2012
    Assignees: Northwestern University, Chiron Corporation
    Inventors: Annelise E. Barron, Ronald N. Zuckermann, Cindy W. Wu
  • Publication number: 20120010145
    Abstract: The disclosure provides a drug composition formulated for inhalation comprising a conjugate of a surface active agent and a pulmonary active drug. The surface active agent has an affinity for the human alveolar/gas interface and comprises at least a portion of a mammalian lung surfactant of a mimic thereof. The disclosure also provides a method of treating a subject suffering from or at risk of suffering from a lung disease comprising administering to the subject a conjugate comprising a drug for lung treatment and a surface active agent by inhalation in an amount effective to induce a drug effect in the lungs.
    Type: Application
    Filed: December 10, 2009
    Publication date: January 12, 2012
    Inventor: Frank Guarnieri
  • Publication number: 20120010126
    Abstract: We describe an rspd(n/CRD) polypeptide, fragment, homologue, variant or derivative thereof for use in a method of treatment or prophylaxis of a disease. A method of treating an individual suffering from a disease or preventing the occurrence of a disease in an individual is also described, in which the method comprises administering to the individual a therapeutically or prophylactically effective amount of an rspd (n/CRD) polypeptide, fragment, homologue, variant or derivative thereof. Preferably, the rspd (n/CRD) polypeptide and nucleic acid comprise SEQ ID NO: 1 and SEQ ID NO: 2, respectively.
    Type: Application
    Filed: February 3, 2011
    Publication date: January 12, 2012
    Applicant: Medical Research Council
    Inventors: Howard Clark, Palaniyar Nadesalingam, Kenneth Bannerman Milne Reid, Peter Strong
  • Patent number: 8084424
    Abstract: Disclosed are methods and compositions related to the production of erythropoietin. The disclosed compositions comprise a poly amino acid. The production of erythropoietin by the disclosed compositions and methods can take place in vivo, in which the proliferation of a subject's erythropoietin-producing cells leads to an increased level of production of erythropoietin, in vitro, in which increased proliferation of cultured erythropoietin-producing cells leads to an increased production of erythropoietin, ex vivo, in which cells or tissues harvested from a subject produce erythropoietin. The disclosed compositions can be administered to a subject or applied to cells or tissues to stimulate increased production of erythropoietin.
    Type: Grant
    Filed: April 9, 2004
    Date of Patent: December 27, 2011
    Assignee: University of Utah Research Foundation
    Inventors: Bellamkonda Kishore, Christof Westenfelder, Jorge Issac
  • Publication number: 20110130333
    Abstract: Administration of a modified natural surfactant in combination with a corticosteroid is effective for the prevention of bronchopulmonary dysplasia (BPD) and lowers the markers of pulmonary oxidative stress.
    Type: Application
    Filed: May 25, 2010
    Publication date: June 2, 2011
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventors: Massimo GIOSSI, Roberta Razzetti, Paolo Chiesi
  • Publication number: 20100317565
    Abstract: The invention relates to novel peptides, which can be used for the production of pharmaceutical compositions. These pharmaceutical compositions can be used for the treatment of edema, in particular pulmonary edema.
    Type: Application
    Filed: June 4, 2008
    Publication date: December 16, 2010
    Applicant: Rentschler Beteiligungs GmbH
    Inventors: Dominik Geiger, Ingeborg Mühldorfer, Jürgen Paal, Klaus P. Schäfer, Jürgen Volz, Rudolf Lucas
  • Publication number: 20100284969
    Abstract: The disclosure provides a drug composition formulated for inhalation comprising a conjugate of a surface active agent and a pulmonary active drug. The surface active agent has an affinity for the human alveolar/gas interface and comprises at least a portion of a mammalian lung surfactant of a mimic thereof. The disclosure also provides a method of treating a subject suffering from or at risk of suffering from a lung disease comprising administering to the subject a conjugate comprising a drug for lung treatment and a surface active agent by inhalation in an amount effective to induce a drug effect in the lungs.
    Type: Application
    Filed: June 4, 2008
    Publication date: November 11, 2010
    Inventor: Frank Guarnieri
  • Publication number: 20100273712
    Abstract: The present invention is directed to the use of pulmonary surfactants, and particularly pulmonary surfactants containing hydrophobic surfactant-associated proteins B, C or both (i.e., surfactants such as calfactant (Infasurf®), to treat PGD and other adverse effects of lung transplantation.
    Type: Application
    Filed: November 23, 2009
    Publication date: October 28, 2010
    Inventor: Edmund A. Egan